Equity Details
Price & Market Data
Price: $6.81
Daily Change: -$0.59 / 8.66%
Daily Range: $6.81 - $7.42
Market Cap: $122,828,336
Daily Volume: 36,616
Performance Metrics
1 Week: -0.14%
1 Month: 27.22%
3 Months: 18.57%
6 Months: 106.7%
1 Year: 41.22%
YTD: -13.96%
About Verrica Pharmaceuticals Inc. (VRCA)
Up-to-date insights on Verrica Pharmaceuticals Inc. (VRCA). Current price: 6.81, daily change: -$0.59 / 8.66%. Market cap: 122,828,336. Performance from 1-month to 1-year.
Company Details
Employees: 76
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.